Using Oasis ECM to treat donor site wounds
Official title: Feasibility Study to Compare OASIS Extracellular Matrix to Standard Wound Care for Treatment of Donor Site Wounds
Run by Cook Biotech Incorporated · NCT04079348 · Data updated 2026-11-12
This study is testing if a new treatment called Oasis ECM can help heal donor site wounds better than regular wound care for people over 16 in the UK.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Cook Biotech Incorporated Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 1 site (Manchester, England) |
| Status | Recruiting |
| Started | November 1, 2020 |
| Main results expected | June 2025 |
| Study ends | December 2025 |
| Registry record updated | December 17, 2024 |
| Trial ID | NCT04079348 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals over 16 years old with a split thickness skin graft donor site wound no larger than 14 x 20 cm.
✕Probably not a fit
Patients with significant co-morbidities that impair wound healing or those under 16 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and effectiveness of Oasis extracellular matrix (ECM) for treating donor site wounds in patients over 16 years old in the United Kingdom. Approximately 40 participants will be enrolled, with half receiving Oasis ECM and the other half receiving standard wound care. The study aims to assess how well Oasis ECM promotes healing in comparison to conventional methods. Participants must have a specific type of skin graft donor site wound that requires a covering material.
Why it matters
Potential benefit: If successful, this treatment could enhance healing outcomes for patients with donor site wounds.
How similar studies have gone: While Oasis ECM is commercially available, this specific application for donor site wounds is being evaluated for the first time in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Has a split thickness skin graft (STSG) donor site wound no greater than 14 x 20 cm in size requiring placement of a covering material. 2. Has at least 24 hours to consent to study participation. Exclusion Criteria: 1. Age \< 16 years 2. Patients who, in the opinion of the investigator, have co-morbidities that impair wound healing, such as: 1. Chronic inflammatory skin condition 2. Chronic liver failure 3. Chronic renal failure 4. Blood-borne viruses (Hep B, Hep C, HIV) 5. Peripheral vascular disease 6. Clinically significant anaemia 7. Uncontrolled diabetes 3. Need for use of the same harvest site (re-cropping) 4. History of radiation therapy to proposed donor site 5. Chronic use of medications known to impair wound healing 6. Chronic use of opioids or neuropathic pain agents 7. Suspected cellulitis, osteomyelitis or septicaemia 8. Patients undergoing haemodialysis 9. Patients requiring spinal/regional block 10. Patients on current anti-coagulant therapy 11. Unable or unwilling to provide informed consent 12. Unable or unwilling to comply with the study follow-up schedule, and procedures 13. Simultaneously participating in another investigational drug or device study (patient must have completed the follow-up phase for the primary endpoint of any previous study at least 30 days prior to enrolment in this study) 14. Allergy or hypersensitivity to materials that are porcine-based 15. Cultural or religious objection to the use of pig or porcine products 16. Known intolerance/allergy to standard wound care products 17. Presence of a local infection at the donor site and/or systemic infection
Where it's running
-
Manchester University NHS Foundation Trust
Manchester, England, United Kingdom Recruiting
Study contacts
- Study coordinator: Carina Gregory, MS
- Email: cgregory@rtix.com
- Phone: 765-497-3355
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
New gel treatment for venous leg ulcers
This study is testing a new gel treatment for people with stubborn venous leg ulcers to see if it helps them heal better than just the usual care.
-
Comparing palatal wound healing in diabetic and non-diabetic patients
This study is testing how well wounds in the mouth heal in people with diabetes compared to those without diabetes after surgery to fix gum issues.
-
4-aminopyridine for faster skin wound healing
This trial will see if 4-aminopyridine helps small skin wounds heal faster in healthy adults aged 18–70.
-
Robot-assisted reconstruction after surgery for rectal or anal cancer
This study is testing if using a muscle flap to rebuild the pelvic floor or vagina after robotic surgery for rectal or anal cancer can improve recovery and quality of life for patients.
-
Predictors of In-Hospital Death in Severe Abdominal Injury
This study will follow adults with severe abdominal trauma at a large Egyptian hospital to see which factors best predict in-hospital death.
-
Humidification methods in trauma ICU patients on mechanical ventilation
This study tests whether active heated humidifiers or passive heat-and-moisture exchangers work better in trauma ICU patients who need long-term mechanical ventilation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.